Finland - Finnish - Fimea (Suomen lääkevirasto)

grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 200 mg - tapentadoli

Finland - Finnish - Fimea (Suomen lääkevirasto)

grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 250 mg - tapentadoli

Finland - Finnish - Fimea (Suomen lääkevirasto)

grünenthal gmbh - tapentadoli hydrochloridum - depottabletti - 25 mg - tapentadoli

European Union - Finnish - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Finland - Finnish - Fimea (Suomen lääkevirasto)

santen oy - dexamethasone sodium phosphate - silmätipat, liuos - 1 mg/ml - deksametasoni

Finland - Finnish - Fimea (Suomen lääkevirasto)

g.l. pharma gmbh - morphini hydrochloridum trihydricum - depottabletti - 10 mg - morfiini

Finland - Finnish - Fimea (Suomen lääkevirasto)

g.l. pharma gmbh - morphini hydrochloridum trihydricum - depottabletti - 30 mg - morfiini

Finland - Finnish - Fimea (Suomen lääkevirasto)

g.l. pharma gmbh - morphini hydrochloridum trihydricum - depottabletti - 60 mg - morfiini

Finland - Finnish - Fimea (Suomen lääkevirasto)

g.l. pharma gmbh - morphini hydrochloridum trihydricum - depottabletti - 100 mg - morfiini

European Union - Finnish - EMA (European Medicines Agency)

accord healthcare s.l.u. - deksmedetomidiini - esilääkitys - psyykenlääkkeiden - sedaatio aikuisten icu (tehohoidossa) potilailla, jotka edellyttävät sedaatiota taso ei syvemmälle kuin kiihottumisen vastauksena sanallinen stimulaatio (vastaa richmond levottomuus-sedaatio scale (rass) 0--3). sedaatio ei-intuboitu aikuisten potilaiden ennen ja/tai sen aikana diagnostisia tai kirurgisia toimenpiteitä, jotka edellyttävät sedaatiota, en. menettelylliset/hereillä sedaatio.